Michael E Johansen1, Kathleen Matic2, Ann Scheck McAlearney3. 1. Department of Family Medicine, College of Medicine, The Ohio State University, Columbus, Ohio. Electronic address: Michael.Johansen@osumc.edu. 2. College of Medicine, The Ohio State University, Columbus, Ohio. 3. Department of Family Medicine, College of Medicine, The Ohio State University, Columbus, Ohio; Division of Health Services Management and Policy, College of Public Health, The Ohio State University, Columbus, Ohio.
Abstract
PURPOSE: The purpose of this study was to determine rates of stimulant/atomoxetine use among teens (aged 12-17 years) and young adults (aged 18-23 years) and to investigate associations in medication use before and after the transition from teen to young adult. METHODS: Repeated cross-sectional analyses using the nationally representative Medical Expenditure Panel Survey. The sample included all teens and young adults between 2003 and 2012. Within this group, a staggered sample of individuals between 2006 and 2012 born during a 5-year range was used to minimize false positive findings due to temporal trends. The primary outcome was attention deficit hyperactivity disorder (ADHD) medication use (two or more prescriptions and ≥60 tablets). A multivariable logistic regression was utilized to determine associations between ADHD medication use and race/ethnicity and other sociodemographic factors. RESULTS: A total of 62,699 individuals were included between 2003 and 2012. Rates of ADHD medication use increased for both teens (4.2%-6.0%) and young adults (1.2%-2.6%) between 2003-2004 and 2011-2012. In adjusted analysis, blacks, Hispanics, and Asians had lower rates of use compared with whites. The decrease in use among young adults was more pronounced among blacks compared with whites. A usual source of care and health insurance were less common among young adults, and both were associated with ADHD medication use. CONCLUSIONS: Although there has been an increase in the use of ADHD medications in both teens and young adults, we found a drop-off in levels of ADHD treatment among young adults when compared with teens. A portion of this decrease appears to be related to race/ethnicity, usual source of care, and health insurance status.
PURPOSE: The purpose of this study was to determine rates of stimulant/atomoxetine use among teens (aged 12-17 years) and young adults (aged 18-23 years) and to investigate associations in medication use before and after the transition from teen to young adult. METHODS: Repeated cross-sectional analyses using the nationally representative Medical Expenditure Panel Survey. The sample included all teens and young adults between 2003 and 2012. Within this group, a staggered sample of individuals between 2006 and 2012 born during a 5-year range was used to minimize false positive findings due to temporal trends. The primary outcome was attention deficit hyperactivity disorder (ADHD) medication use (two or more prescriptions and ≥60 tablets). A multivariable logistic regression was utilized to determine associations between ADHD medication use and race/ethnicity and other sociodemographic factors. RESULTS: A total of 62,699 individuals were included between 2003 and 2012. Rates of ADHD medication use increased for both teens (4.2%-6.0%) and young adults (1.2%-2.6%) between 2003-2004 and 2011-2012. In adjusted analysis, blacks, Hispanics, and Asians had lower rates of use compared with whites. The decrease in use among young adults was more pronounced among blacks compared with whites. A usual source of care and health insurance were less common among young adults, and both were associated with ADHD medication use. CONCLUSIONS: Although there has been an increase in the use of ADHD medications in both teens and young adults, we found a drop-off in levels of ADHD treatment among young adults when compared with teens. A portion of this decrease appears to be related to race/ethnicity, usual source of care, and health insurance status.
Authors: Laura C Hart; Scott D Grosse; Melissa L Danielson; Rebecca A Baum; Alex R Kemper Journal: J Atten Disord Date: 2020-09-18 Impact factor: 3.256
Authors: Brooke S G Molina; Heather M Joseph; Heidi L Kipp; Rachel A Lindstrom; Sarah L Pedersen; David J Kolko; Daniel J Bauer; Geetha A Subramaniam Journal: J Dev Behav Pediatr Date: 2021-09-01 Impact factor: 2.988
Authors: Silviu Grisaru; Melissa Yue; Susan M Samuel; Kathleen H Chaput; Lorraine A Hamiwka Journal: Paediatr Child Health Date: 2018-03-05 Impact factor: 2.253